Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

Select a cancer below for additional information on ORP active trials at NCCN Member Institutions.

Breast Cancer

Mihaela Cristea, MDCity of Hope National Medical CenterA Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRα-positive Recurrent Ovarian, Primary Peritoneal, Fallopian tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

Gastrointestinal

Christos Fountzilas, MDRoswell Park Comprehensive Cancer CenterA Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)
Amit Mahipal, MBBS, MPHMayo Clinic Cancer CenterPhase II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Biliary Tract Cancers
Sarbajit Mukherjee, MD, MSRoswell Park Comprehensive Cancer CenterUse of Trifluridine/tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma

Gynecologic Cancer

Mihaela Cristea, MDCity of Hope National Medical CenterA Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRα-positive Recurrent Ovarian, Primary Peritoneal, Fallopian tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)
Shannon Westin, MDThe University of Texas MD Anderson Cancer CenterA Phase II with a Limited Safety Lead-In of Enzalutamide in Combination with Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrial Cancer

Head and Neck Cancers

Aarti Bhatia, MD, MPHYale Cancer Center/Smilow Cancer HospitalSingle-Arm Phase II Trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck

Lung Cancer

Yasir Elamin, MDThe University of Texas MD Anderson Cancer CenterRandomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR)
Sally York, MDVanderbilt-Ingram Cancer CenterPhase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs
Pasi Janne, MDDana-Farber/Brigham and Women's Cancer Center/ Massachusetts General HospitalA Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer
Joseph Treat, MDFox Chase Cancer CenterTH-138: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, with or without atezolizumab in stage IV non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked